Search for Clinical Trial Results

Sponsored By

Morphea - 14 Studies Found

Status Study
Withdrawn Study Name: Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study
Condition: Morphea
Date: 2005-09-28
Interventions: Drug: imiquimod 5% cream (Aldara)
Completed Study Name: Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
Condition: Symmetric Limited Morphea.
Date: 2008-12-18
Interventions:
  • Other: Medium Dose UVA-1 UVA-1
Terminated Study Name: Molecular Effects of Topical Calcipotriene on Morphea
Condition:
  • Morphea
  • Localized Scleroderma

    • Date: 2015-03-03
    Interventions: Drug: topical calcipotriene 0.005% ointment Affected area will be treated twice daily for 3 months
Recruiting Study Name: Genetic Variants in Linear Localized Scleroderma
Condition: Morphea
Date: 2014-07-21
Interventions: Other: skin biopsy
Recruiting Study Name: Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma
Condition: Localized Scleroderma
Date: 2013-09-05
Interventions:
  • Device: Fractional carbon dioxide laser

Recruiting Study Name: Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
Condition:
  • Scleroderma, Localized
  • Morphea
  • Procedure: UVA-1 Phototherapy
  • Procedure: P
Recruiting Study Name: Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Condition:
  • Scleroderma, Localized
  • Morphea
  • Scleroderma, Localized
  • Scleroderma
Completed Study Name: Imiquimod in Children With Plaque Morphea
Condition: Scleroderma, Localized
Date: 2005-09-02
Interventions: Drug: Imiquimod 5% cream Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimo
Withdrawn Study Name: Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea
Condition: Scleroderma
Date: 2016-02-09
Interventions:
  • Drug: Clobetasol ointment, twi
Withdrawn Study Name: A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
Condition: Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)
Date: 2009-07-09
Interventions: Drug: Rituximab Mabthera, Rituximab 1000 mg I.V.
Next >>>